Seeing your primary care doctor shouldn’t feel like speed dating—right? Justin and Todd are joined by Beth Holmes, head of network development at Hint Health, to discuss how direct primary care (DPC) aims to revitalize old-school doctor-patient relationships and fill the gaps left by the fee-for-service model. Beth discusses DPC’s success with smaller employers and underinsured regions, how DPC reduces reliance on emergency care, and why family doctors may be less likely to leave the field in a DPC model.

Beth, Justin, and Todd examine some tricky questions facing this emerging care model: Who are the right patients for DPC’? How do we accurately track outcomes for a care model that doesn’t deliver claims data? And why should an employer think about offering DPC as a benefit to its employees when it already offers health insurance?

Justin, Todd, and special guest Robert Groebel, VP of global life science strategy at Definitive Healthcare, expand on last week’s chat with Pam Randhawa from Empiriko and unpack the challenges, benefits, and opportunities of collaboration in the biopharma market.  

How can big pharma, small pharma, academia, and the government all work together?  Robert and Todd have some big ideas. They look back at their careers to share professional insights and personal perspectives on the biopharma industry’s evolving playbook—and why they’re looking forward with a healthy dose of optimism.   

Justin asks Todd and Robert to answer some big questions: What can biopharma orgs do to address healthcare equity? Is there an insurmountable divide between the industry’s profit motive and academia’s educational mission? And what has Robert feeling so optimistic about biopharma’s impact on patients and caregivers?

The life sciences industry is seeing the convergence of some revolutionary technology, but is it bringing the right people together? Pam Randhawa, CEO and founder of Empiriko, stops by to chat about the need for closer collaboration across the biopharma space—between big and small organizations, academic institutions and startups, and the public and private sectors. Pam and Justin discuss the mutual benefits of partnerships between new and established biopharma organizations, academia’s untapped potential in life sciences R&D, and why Massachusetts is the model for cross-sector collaboration and innovation.

Plus, Pam answers some of Justin’s most pressing questions: How are biological models shaping clinical care? What can biopharma entrepreneurs learn from a 20-year industry veteran? And what will it take to make the Commonwealth the world’s No. 1 life sciences innovator?